Advertisement

World Journal of Pediatrics

, Volume 11, Issue 4, pp 338–345 | Cite as

Clinicopathological features and prognosis of membranoproliferative-like Henoch-Schönlein purpura nephritis in children

  • Yan-Jie HuangEmail author
  • Xiao-Qing Yang
  • Wen-Sheng Zhai
  • Xian-Qing Ren
  • Qing-Yin Guo
  • Xia Zhang
  • Meng Yang
  • Tatsuo Yamamoto
  • Yuan Sun
  • Ying Ding
Original article

Abstract

Background

The aim of this retrospective study was to define the clinical manifestations, pathological features and prognosis of children with membranoproliferativelike Henoch-Schönlein purpura nephritis (HSPN), representing International Study of Kidney Disease in Children (ISKDC) grade VI.

Methods

Among 245 patients with HSPN treated in our hospital between 2008 and 2010, nine patients (3.7%) were diagnosed with HSPN of ISKDC grade VI (males=5, females=4, age: 9.5±2.03 years, mean±SD). The clinical features, laboratory and pathological findings, treatment and outcome of the 9 patients were retrospectively analyzed.

Results

Of the 9 patients, 7 (78%) presented with hematuria and nephrotic syndrome, and were treated with steroids (oral prednisone or intravenous methylprednisolone pulse therapy) and immunosuppressants (oral tripterygium glycosides or intravenous cyclophosphamide pulse therapy). One (11%) patient had hematuria and nephrotic range proteinuria (>50 mg/kg per 24 hours) and was treated with oral prednisone and tripterygium glycosides. Another (11%) patient presented with hematuria and moderate proteinuria (25-50 mg/kg per 24 hours) and was treated with oral tripterygium glycoside only. Histopathological examination showed diffuse glomerular mesangial and endocapillary proliferation, mesangial interposition, double-contour formation, podocyte hypertrophy, shedding, and cytoplasmic absorption droplets. The percentages of glomeruli with small cellular crescents varied from 4%-25% in 6 of 9 patients. Follow-up for 2 to 4 years showed excellent recovery in all patients.

Conclusions

The main clinical feature of ISKDC grade VI HSPN in children is a nephrotic syndrome with hematuria. The excellent prognosis of the disease was probably related to early diagnosis and treatment with steroids and/or immunosuppressants, and mild degree of glomerulosclerosis and tubulointerstitial damage.

Keywords

clinicopathological features Henoch-Schönlein purpura nephritis prognosis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Saulsbury FT. Henoch-Schönlein purpura in children: Report of 100 patients and review of the literature. Medicine 1999;78:395–409.CrossRefPubMedGoogle Scholar
  2. 2.
    Neilsen HE. Epidemiology of Schönlein-Henoch purpura. Acta Paediatr Scand 1998;77:125–131.CrossRefGoogle Scholar
  3. 3.
    Stewart M, Savage JM, Bell B, McCord B. Long term renal prognosis of Henoch-Schönlein purpura in an unselected childhood population. Eur J Pediatr 1988;147:113–115.CrossRefPubMedGoogle Scholar
  4. 4.
    Narchi H. Risk of long term renal impairment and duration of follow up recommended for Henoch-Schonlein purpura with normal or minimal urinary findings: a systematic review. Arch Dis Child 2005;90:916–920.PubMedCentralCrossRefPubMedGoogle Scholar
  5. 5.
    Yoshikawa N, White RH, Cameron AH. Prognostic signifi cance of the glomerular changes in Henoch-Schoenlein nephritis. Clin Nephrol 1981;16:223–229.PubMedGoogle Scholar
  6. 6.
    Counahan R, Winterborn MH, White RH, Heaton JM, Meadow SR, Bluett NH, et al. Prognosis of Henoch–Schönlein nephritis in children. Br Med J 1977;2:11–14.PubMedCentralCrossRefPubMedGoogle Scholar
  7. 7.
    Hass M. Henoch-Schönlein purpura nephritis. In: Ennete JC, Olsen JL, Schwartz MM, Silva FG, eds. Heptinstall’s pathology of the kidney. Philadelphia: Lippincott Williams & Wilkins, 2007: 423–486.Google Scholar
  8. 8.
    Habib R, Niaudet R, Levy M. Schoenlein-Henoch purpura nephritis and IgA nephropathy. In: Tisher CC, Brenner BM, eds. Renal pathology with clinical and functional correlations. Philadelphia: Lippincott, 1994: 472–523.Google Scholar
  9. 9.
    Soylemezoglu O, Ozkaya O, Ozen S, Bakkaloglu A, Dusunsel R, Peru H, et al. Henoch-Schönlein nephritis: a nationwide study. Nephron Clin Pract 2009;112:199–204.CrossRefGoogle Scholar
  10. 10.
    Rai A, Nast C, Adler S. Henoch-Schönlein Purpura Nephritis. J Am Soc Nephrol 1999;10:2637–2644.PubMedGoogle Scholar
  11. 11.
    Heaton J, Turner DR, Cameron JS. Localization of glomerular "deposits" in Henoch—Schönlein nephritis. Histopathology 1977;1:93–104.CrossRefPubMedGoogle Scholar
  12. 12.
    Levy M, Broyer M, Arsan A, Levy-Bentolila D, Habib R. Anaphylactoid purpura nephritis in childhood: natural history and immunopathology. Adv Nephrol Necker Hosp 1976;6:183–228.PubMedGoogle Scholar
  13. 13.
    Mills JA, Michel BA, Bloch DA, Calabrese LH, Hunder GG, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classifi cation Henoch-Schönlein purpura. Arthritis Rheum 1990;33:1114–1121.CrossRefPubMedGoogle Scholar
  14. 14.
    Dillon MJ, Ozen S. A new international classification of childhood vasculitis. Pediatr Nephrol 2006;21:1219–1222.CrossRefPubMedGoogle Scholar
  15. 15.
    RobertsI S, Cook HT, Troyanov S, Alpers CE, Amore A, Barratt J, et al. The Oxford classifi cation of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int 2009;76:546–556.CrossRefGoogle Scholar
  16. 16.
    Cattran DC, Coppo R, Cook HT, Feehally J, Roberts IS, Troyanov S, et al. The Oxford classifi cation of IgA nephropathy: Rationale, clinicopathological correlations, and classification. Kidney Int 2009;76:534–545.CrossRefPubMedGoogle Scholar
  17. 17.
    Andreoli SP, Bergstein JM. Treatment of severe IgA nephrology in children. Pediatr Nephrol 1989;3:248–253.CrossRefPubMedGoogle Scholar
  18. 18.
    Foster BJ, Bernard C, Drummond KN, Sharma AK. Effective therapy for severe Henoch-Schönlein purpura nephritis with prednisone and azathioprine: a clinical and histopathologic study. J Pediatr 2000;136:370–375.CrossRefPubMedGoogle Scholar
  19. 19.
    Li LS, Zhang X, Chen GY. Clinical study of Tripterygium wifordii Hook in the treatment of nephritis. Chin J Intern Med 1981;20:216–220.CrossRefGoogle Scholar
  20. 20.
    Wan Y, Sun W, Zhang H, Yan Q, Chen P, Dou C, et al. Multiglycoside of Tripterygium wilfordii Hook f. ameliorates prolonged mesangial lesions in experimental progressive glomerulonephritis. Nephron Exp Nephrol 2010;114:e7–e14.CrossRefPubMedGoogle Scholar
  21. 21.
    Chen ZH, Qin WS, Zeng CH, Zheng CX, Hong YM, Lu YZ, et al. Triptolide reduces proteinuria in experimental membranous nephropathy and protects against C5b-9-induced podocyte injury in vitro. Kidney Int 2010;77:974–988.CrossRefPubMedGoogle Scholar
  22. 22.
    Wan YG, Zhao Q, Sun W, Zhang HL, Li M, Wei QX, et al. Contrasting dose-effects of multi-glycoside of Tripterygium wilfordii HOOK. f. on glomerular inflammation and hepatic damage in two types of anti-Thy1.1 glomerulonephritis. J Pharmacol Sci 2012;118:433–446.CrossRefPubMedGoogle Scholar
  23. 23.
    Assadi F. Childhood Henoch-Schönlein Nephritis: A multivariate analysis of clinical features and renal morphology at disease onset. Iran J Kidney Dis 2009;3:17–21.PubMedGoogle Scholar
  24. 24.
    Ohara S, Kawasaki Y, Matsuura H, Oikawa T, Suyama K, Hosoya M. Successful therapy with tonsillectomy for severe ISKDC grade VI Henoch-Schönlein purpura nephritis and persistent nephrotic syndrome. Clin Exp Nephrol 2011;15:749–753.CrossRefPubMedGoogle Scholar
  25. 25.
    Lee KA, Ha TS. A case of hypocomplementemic Henoch-Schönlein purpura presenting features of membranoproliferative glomerulonephritis. Korean J Pediatr 2005;48:81–84.Google Scholar
  26. 26.
    Schlöndorff D, Banas B. The mesangial cell revisited: No cell is an island. J Am Soc Nephrol 2009;20:1179–1187.CrossRefPubMedGoogle Scholar
  27. 27.
    Wang C, Liu X, Peng H, Tang Y, Tang H, Chen Z, et al. Mesangial cell stimulated by immunoglobin A1 from IgA nephropathy upregulate transforming growth factor beta1 synthesis in podocytes via renin-angiotensin system activation. Arch med Res 2010;41:255–260.CrossRefPubMedGoogle Scholar
  28. 28.
    Shankland SJ. The podocyte’s response to injury: role in proteinuria and glomerulosclerosis. Kidney Int 2006;69:2131–2147.CrossRefPubMedGoogle Scholar
  29. 29.
    Patrakka J, Tryggvason K. New insights into the role of podocytes in proteinuria. Nat Rev Nephrol 2009;5:463–468.CrossRefPubMedGoogle Scholar
  30. 30.
    Kinoue K, Hattori M, Horita S, Kawaguchi H, Ito K. Crescent formation in children with Henoch-Schönlein purpura nephritis: a pathological and immunohistochemical study. Nihon Jinzo Gakkai Shi 1996;38:364–371.PubMedGoogle Scholar
  31. 31.
    Pillebout E, Alberti C, Guillevin L, Ouslimani A, Thervet E. Addition of cyclophosphamide to steroids provides no benefit compared with steroids alone in treating adult patients with severe Henoch Schönlein Purpura. Kidney Int 2010;78:495–502.CrossRefPubMedGoogle Scholar
  32. 32.
    Shenoy M, Bradbury MG, Lewis MA, Webb NJ. Outcome of Henoch-Schönlein purpura nephritis treated with long-term immunosuppression. Pediatr Nephrol 2007;22:1717–1722.CrossRefPubMedGoogle Scholar
  33. 33.
    Kawasaki Y, Suyama K, Yugeta E, Katayose M, Suzuki S, Sakuma H, et al. The incidence and severity of Henoch-Schönlein purpura nephritis over a 22-year period in Fukushima Prefecture. Int Urol Nephrol 2010;42:1023–1029.CrossRefPubMedGoogle Scholar
  34. 34.
    Coppo R, Amore A, Gianoglio B, Cacace G, Picciotto G, Roccatello D, et al. Angiotensin II local hyperreactivity in the progression of IgA nephropathy. Am J Kidney Dis 1993;21:593–602.CrossRefPubMedGoogle Scholar
  35. 35.
    Del Prete D, Gambaro G, Lupo A, Anglani F, Brezzi B, Magistroni R, et al. Precocious activation of genes of the renin-angiotensin system and the fibrogenic cascade in IgA glomerulonephritis. Kidney Int 2003;64:149–159.CrossRefPubMedGoogle Scholar
  36. 36.
    Flynn JT, Smoyer WE, Bunchman TE, Kershaw DB, Sedman AB. Treatment of Henoch-Schönlein Purpura glomerulonephritis in children with high-dose corticosteroids plus oral cyclophosphamide. Am J Nephrol 2001;21:128–133.CrossRefPubMedGoogle Scholar
  37. 37.
    Wan Y, Gu L, Suzuki K, Karasawa T, Fujioka Y, Han GD, et al. Multi-glycoside of Tripterygium wilfordii Hook f. ameliorates proteinuria and acute mesangial injury induced by anti-Thy1.1 monoclonal antibody. Nephron Exp Nephrol 2005;99:121–129.CrossRefGoogle Scholar
  38. 38.
    Goldstein AR, White RH, Akuse R, Chantler C. Long-Term follow-up of childhood Henoch-Schönlein purpura nephritis. Lancet 1992;339:280–282.CrossRefPubMedGoogle Scholar
  39. 39.
    Hodgkins KS, Schnaper HW. Tubulointerstitial injury and the progression of chronic kidney disease. Pediatr Nephrol 2012; 27:901–909.PubMedCentralCrossRefPubMedGoogle Scholar
  40. 40.
    Nath KA. Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kidney Dis 1992;20:1–17.CrossRefPubMedGoogle Scholar
  41. 41.
    Nangaku M. Mechanisms of tubulointerstitial injury in the kidney: fi nal common pathways to end-stage renal failure. Intern Med 2004;43:9–17.CrossRefPubMedGoogle Scholar

Copyright information

© Children's Hospital, Zhejiang University School of Medicine and Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Yan-Jie Huang
    • 1
    • 2
    Email author
  • Xiao-Qing Yang
    • 1
    • 2
  • Wen-Sheng Zhai
    • 1
    • 2
  • Xian-Qing Ren
    • 1
    • 2
  • Qing-Yin Guo
    • 1
    • 2
  • Xia Zhang
    • 1
    • 2
  • Meng Yang
    • 1
    • 2
  • Tatsuo Yamamoto
    • 1
    • 3
  • Yuan Sun
    • 1
    • 4
  • Ying Ding
    • 1
    • 2
  1. 1.ZhengzhouChina
  2. 2.Department of PediatricsFirst Affiliated Hospital of Henan University of Traditional Chinese MedicineBeijingChina
  3. 3.Second Department of MedicineNumazu City HospitalNumazuJapan
  4. 4.Department of AnesthesiaStanford University School of MedicineCaliforniaUSA

Personalised recommendations